13 results
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free ... Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
Risk and Type of Progression ... #EBM #Honc #MGUS ... #Progression #IgM ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Cumulative Incidence of Progression ... Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Lung Cancer - Progression-free ... #EBM #Honc #PACIFIC ... Durvalumab #NSCLC #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Clinical image showing neck seat belt sign (diagonal abrasions are present along the course of the
artery injury is CT angiography ... #EM #Clinical #Trauma ... emergency #Neck #Photo
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... VisualAbstract #NEJM
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the
Intention-to-Treat Population #EBM ... #Honc #Nivolumab ... Ipilimumab #Melanoma #NEJM
Diffuse Melanosis Cutis - Several weeks earlier, a progressive gray–blue discoloration of the skin had developed.
weeks earlier, a progressive ... Clinical #Derm #Honc ... Hyperpigmentation #NEJM